SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350: 15351548.
  • 2
    Schrappe M, Reiter A, Zimmerman M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000; 14: 22052222.
  • 3
    Henze G, Fendler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group. Blood. 1991; 78: 1661172.
  • 4
    Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994; 331: 12531258.
  • 5
    Pui C-H, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St. Jude Children's Research Hospital. Leukemia. 2000; 14: 22862294.
  • 6
    Behm FG, Raimondi SC, Schell MK, Look AT, Rivera GK, Pui C-H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic factors. Blood. 1992; 79: 10111016.
  • 7
    MitelmanF, editor. International System for Human Cytogenetic Nomenclature (ICSN): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tenn., October 1994. Basel: S. Karger, 1995: 114.
  • 8
    Pinkel D. Five-year follow up of “total therapy”of childhood lymphocytic leukemia. JAMA. 1971; 216: 648652.
  • 9
    Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991; 337: 6166.
  • 10
    Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998; 338: 499505.
  • 11
    Pui C-H, Relling MV, Behm FG, et al. L-asparaginase may potentiate the leukemogenic effect of epipodophyllotoxins. Leukemia. 1995; 9: 16801684.
  • 12
    Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980: 163188.
  • 13
    Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 14
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 15
    Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974; 345: 8186.
  • 16
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496450.
  • 17
    Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187220.
  • 18
    Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ. Re-induction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. Blood. 1988; 72: 12861292.
  • 19
    Abshire TC, Pollock BH, Billet AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000; 96: 17091715.
  • 20
    Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer. 1998; 82: 13871395.
  • 21
    Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002; 100: 5258.
  • 22
    Cave H, Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 591598.
  • 23
    Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood. 2002; 99: 43864393.
  • 24
    van Dongen J, Seriu T, Panxer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352: 17311738.
  • 25
    Coustan-Smith E, Gajjar A, Hijiya N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia. 2004; 18: 499504,
  • 26
    Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001; 358: 12391241.
  • 27
    Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood. 1996; 88: 831837.
  • 28
    Chessels JM, Leiper AD, Richards SM. A second course of treatment for childhood acute lymphoblastic leukemia: long term follow up is needed to assess results. Br J Haematol. 1994; 86: 4854.
  • 29
    Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood. 2003; 101: 38353839.
  • 30
    von Stackelberg A, Hartmann R, Herold R, et al. Outcome after relapse of T-cell acute lymphoblastic leukemia in childhood. A report from the BFM Relapse Study Group [abstract]. Med Pediatr Oncol. 2000; 35: 250.
  • 31
    Beyermann B, Agthe AG, Adams HP, et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. Blood. 1996; 87: 15321538.
  • 32
    Loh ML, Silverman LB, Young ML, et al. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998; 92: 47924797.
  • 33
    Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia. 1999; 13: 1921.
  • 34
    Seeger K, von Stackelberg A, Taube T, et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol. 2001; 19: 31883193.
  • 35
    Buhrer C, Hartmann R, Fengler R, et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1993; 21: 470476.
  • 36
    Pui C-H, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998; 92: 411415.
  • 37
    Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 16631671.
  • 38
    Maloney DH, Shuster JJ, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group Phase III Trial. J Clin Oncol. 1998; 16: 246254.
  • 39
    Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German–Austrian–Swiss ALL-BFM Study Group. Blood. 2000; 95: 33103322.
  • 40
    Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001; 97: 12111218.
  • 41
    Pui C-H, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood. 2004; 104: 26902696.
  • 42
    Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999; 93: 31673215.
  • 43
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10311037.
  • 44
    Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003; 3: 173183.
  • 45
    Yeoh EJ, Ross ME, Shurtleff S, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1: 133143.
  • 46
    Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1: 113.
  • 47
    Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351: 533542.